2 results
Approved WMOCompleted
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
Approved WMOCompleted
To explore the safety and feasibility of continuous and intermittent hypoxia therapy in PD and the differences of symptom modification of different hypoxia protocols. Secondary outcomes include exploring the responsiveness of subjective and…